Skip to main content

IIEF-5 / SHIM

The IIEF-5, also known as the Sexual Health Inventory for Men (SHIM), is a 5-item abridged version of the 15-item IIEF questionnaire. It classifies erectile dysfunction as severe (5–7), moderate (8–11), mild-to-moderate (12–16), mild (17–21), or no ED (22–25). It is the most widely used ED screening tool. Cardiovascular disease is the leading organic cause of ED — assess 10-year risk with ASCVD Risk Calculator and Framingham Risk Score. Screen for depression, a common cause and consequence of ED, with PHQ-9. Assess voiding symptoms with IPSS Calculator. Metabolic syndrome increases ED risk — calculate BMI Calculator.

Formula: Sum of 5 items (each 1–5). Total: 5–25. No ED ≥22, Mild 17–21, Mild-Mod 12–16, Moderate 8–11, Severe 5–7.

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

How It Works

1

Patient answers 5 questions about the past 4 weeks

The questionnaire asks about confidence in achieving an erection, firmness of erections, ability to maintain erections during penetration, satisfaction with the ability to maintain erections, and overall satisfaction with sexual intercourse. Each item is scored 1–5 (1 = almost never/very poor, 5 = almost always/very high).

2

Sum for total score (5–25)

Add all five item scores. The validated diagnostic cutoff for erectile dysfunction is a total score of 21 or below. Any score ≤21 indicates some degree of ED.

3

Classify severity and guide management

22–25: no ED; 17–21: mild; 12–16: mild-to-moderate; 8–11: moderate; 5–7: severe. Severity guides treatment selection: mild-to-moderate typically responds to PDE5 inhibitors (sildenafil, tadalafil). Severe ED with poor PDE5i response warrants penile Doppler ultrasound and possible specialist referral.

Who Uses the IIEF-5 / SHIM

Initial ED Evaluation

Urologists, primary care physicians, endocrinologists

The IIEF-5 is the AUA-recommended standard screening tool for erectile dysfunction. Use at the initial visit to establish severity, guide discussion about organic vs psychogenic ED, and check cardiovascular risk with [ASCVD Risk Calculator](/tools/ascvd-risk) — ED is often the first manifestation of vascular disease.

PDE5 Inhibitor Treatment Monitoring

Urologists, primary care physicians

Reassess IIEF-5 at 4–8 weeks after starting sildenafil, tadalafil, or vardenafil. A clinically meaningful improvement is generally considered a ≥4-point increase. Inadequate response at maximum dose warrants further workup.

Post-Prostatectomy Penile Rehabilitation

Urologic oncologists, reconstructive urologists

Baseline IIEF-5 before radical prostatectomy establishes preoperative erectile function. Serial post-operative IIEF-5 scores track nerve recovery, guide timing of penile rehabilitation (PDE5 inhibitors, vacuum erection devices), and set realistic expectations for functional recovery.

Cardiovascular Risk Screening

Cardiologists, internists

Erectile dysfunction is an independent predictor of cardiovascular events. ED precedes coronary artery disease by 2–5 years on average. In any man with new ED, especially under age 60, perform a full cardiovascular risk assessment using [ASCVD Risk Calculator](/tools/ascvd-risk) and [Framingham Risk Score](/tools/framingham-risk).

Mental Health Comorbidity Assessment

Psychiatrists, psychologists, primary care

Depression and ED are bidirectional — depression causes ED, and ED causes depression. For patients with significant ED alongside low libido, screen with [PHQ-9](/tools/phq9). Psychogenic ED (normal nocturnal erections, situational) responds to psychotherapy; organic ED requires medical treatment.

Pro Tips

1

ED is often the earliest symptom of cardiovascular disease

Penile arteries are smaller than coronary arteries — endothelial dysfunction manifests in the penis 2–5 years before cardiac symptoms. New-onset ED in men under 60 should trigger comprehensive cardiovascular risk assessment. Treating the underlying vascular risk often improves erectile function alongside PDE5 inhibitors.

2

Check testosterone in all men with new-onset ED

Hypogonadism is present in approximately 10–15% of men with ED. Low testosterone reduces the response to PDE5 inhibitors. Draw morning total testosterone (before 10 AM) in all new ED patients. Testosterone replacement in hypogonadal men often restores PDE5i efficacy.

3

PDE5 inhibitors are absolutely contraindicated with nitrates

Sildenafil, tadalafil, and vardenafil cause profound hypotension in combination with organic nitrates (nitroglycerin, isosorbide mononitrate). Always screen for nitrate use before prescribing. Men taking nitrates for angina who want ED treatment require cardiology consultation for nitrate substitution strategies.

4

Tadalafil 5 mg daily treats both ED and BPH simultaneously

Once-daily tadalafil is FDA-approved for both erectile dysfunction and BPH-related lower urinary tract symptoms. For men with coexisting ED and LUTS (assessed with [IPSS Calculator](/tools/ipss)), daily tadalafil may address both conditions and is preferred over on-demand dosing.

5

Nocturnal erections preserved = psychogenic ED

Men with organic (vascular or neurogenic) ED lose nocturnal penile tumescence. Men with psychogenic ED typically have normal or near-normal nocturnal erections but fail to achieve erections in sexual situations. Asking about morning erections helps distinguish organic from psychogenic etiology, directing toward either medical or psychological treatment.

6

Post-prostatectomy ED: nerve-sparing vs non-nerve-sparing determines prognosis

After bilateral nerve-sparing radical prostatectomy, approximately 70% of men recover functional erections within 18–24 months with penile rehabilitation. Non-nerve-sparing procedures have much lower recovery rates. Preoperative IIEF-5 and nerve-sparing status together predict postoperative functional outcomes.

Common Questions About Your Results

Evidence-Based Methodology

The IIEF-5 (SHIM) was derived from the full 15-item IIEF by Rosen et al. (1999) in a sample of 1,152 men. The Massachusetts Male Aging Study (Feldman 1994) established prevalence data: ED affects approximately 52% of men aged 40–70. The Princeton Consensus (2012) established the cardiovascular risk assessment framework for men with ED prior to PDE5 inhibitor prescribing.

Clinical Content Trust

Last reviewed:
April 21, 2026
Guideline version:
General evidence framework v2026.04
Source set version:
Primary-source set v1

How to Interpret Your Result

Your IIEF-5 score classifies erectile function on a spectrum from normal to severely impaired. A score of 22 to 25 indicates no erectile dysfunction. A score of 17 to 21 indicates mild ED, where erections are generally sufficient but occasionally unreliable. A score of 12 to 16 indicates mild-to-moderate ED, with more frequent difficulty achieving or maintaining erections adequate for satisfactory intercourse. A score of 8 to 11 indicates moderate ED, where erectile difficulties are present in most attempts. A score of 5 to 7 indicates severe ED, with erections rarely adequate for penetration.

The validated diagnostic cutoff for erectile dysfunction is a score of 21 or below. However, clinical significance depends on individual context — a patient's baseline expectations, relationship factors, and the degree to which erectile difficulty causes distress all inform treatment decisions. Serial IIEF-5 scores are useful for monitoring response to PDE5 inhibitors, penile rehabilitation programs, or recovery after pelvic surgery.

When to Use This Tool

The IIEF-5 is the standard screening tool for erectile dysfunction in clinical practice. It should be used at the initial evaluation of any man presenting with ED complaints, during pre-operative assessment before radical prostatectomy or other pelvic surgery (to establish a baseline), and at follow-up visits to objectively measure treatment response to PDE5 inhibitors (sildenafil, tadalafil), intracavernosal injections, or vacuum devices.

It is also widely used in clinical trials as a primary or secondary outcome measure for ED treatments. In primary care, it provides an efficient, standardized way to quantify ED severity and facilitate conversations about sexual health that patients may otherwise find difficult to initiate.

Limitations

The IIEF-5 focuses specifically on erectile function and does not assess other domains of sexual health such as libido, orgasmic function, ejaculatory function, or overall sexual satisfaction. Men with premature ejaculation, low desire, or anorgasmia may score normally on the IIEF-5 despite significant sexual dysfunction. The full 15-item IIEF covers these additional domains.

The questionnaire requires recent sexual activity or attempts for meaningful responses. Men who have not been sexually active may have difficulty answering, and their scores may not accurately reflect erectile capacity. The scoring also does not distinguish between organic and psychogenic erectile dysfunction, which require different treatment approaches.

Partner-related factors, relationship quality, and situational circumstances can significantly influence responses. The IIEF-5 captures the patient's subjective perception, which may differ from objective erectile function as measured by nocturnal penile tumescence testing or penile Doppler ultrasound.

For related assessments, see IPSS Score and PSA Density.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

  1. April 21, 2026 · trust-baseline

    Clinical trust metadata enabled for this tool page with structured review/version fields.

Frequently Asked Questions